Apotex Q2 adjusted EBITDA excluding VLLP rises 19% to CAD 279.8 million
Apotex Q2 adjusted EBITDA excluding VLLP rises 19% to CAD 279.8 million Apotex’s second-quarter
Apotex Q2 adjusted EBITDA excluding VLLP rises 19% to CAD 279.8 million Apotex’s second-quarter